Home Search
dbv - search results
If you're not happy with the results, please do another search
Can Peanut Allergy Be Changed in Infancy? DBV’s THRIVE Trial Tests a Bold New...
Researchers are testing whether starting peanut patch therapy in infancy can permanently change the course of peanut allergy.
DBV Launches Peanut Patch Study in Infants as Young as Six Months
DBV Technologies has screened the first participant in a pioneering trial of its peanut allergy patch for infants.
DBV to Submit FDA Application After Viaskin Peanut Patch Achieves Goals in Phase 3...
Many of the children treated with the patch were able to tolerate significantly more peanut protein than they could before the study.
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12.
DBV Confirms Alignment with FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in...
Toddlers study on-track to initiate in 2Q 2025.
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and...
Company to pursue an Accelerated Approval pathway for toddlers ages 1–3 years-old.
DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler Study
81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
DBV Outlines Path to Regulatory Approval of Viaskin Peanut Patch
Are Viaskin therapies finally on the horizon?
FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial to Commence
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Private Law Firm to Investigate Claims on Behalf of Investors in DBV Technologies
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.
We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.
Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.
Please see our Terms of Service and Privacy Policy.
Copyright ©2011-2024 SnackSafely.com, Inc — All rights reserved